[ET Net News Agency, 3 January 2022] Kintor Pharmaceutical Limited (09939) said the
company has on 31 December 2021 enrolled and dosed the first patient in the phase III
clinical trial of pyrilutamide (KX-826), its in-house developed and potential
first-in-class topical drug globally, for the treatment of male androgenetic alopecia
(AGA) patients.
KX-826 is the first androgen receptor (AR) antagonist that has entered the pivotal phase
III clinical trial for AGA treatment in China and globally. (RC)